The European Branch of an International Pharmaceutical Company Wants to Increase Doctor’s Engagement

Introduction
The company is a global, science-driven pharmaceutical company at the forefront of medical innovation, dedicated to improving the health and well-being of people worldwide. With a rich history, it has grown into one of the world’s leading biopharmaceutical firms, distinguished by its unwavering commitment to cutting-edge research, development, and commercialization of life-changing medicines.

The company operates in more than 100 countries, collaborating with healthcare professionals, institutions, and organizations to ensure their medicines reach those who need them most. Their commitment to patients extends beyond the laboratory, as they strive to make their treatments accessible and affordable to people from all walks.

Challenge
The COVID-19 pandemic has had a profound impact on business and physical communication. Social distancing measures and lockdowns forced companies to adapt rapidly to doing business remotely. Many doctor’s meetings and conferences shifted to virtual platforms, reducing in-person interactions. Businesses embraced remote work, accelerating the adoption of digital communication tools.

While this preserved business continuity, it also highlighted the importance of human connection. The absence of face-to-face interactions affected networking, team dynamics, and creative collaboration. As the world reopens, the company is reevaluating the communication strategies, seeking a balance between digital efficiency and the irreplaceable value of in-person connections.

Read more about how this pharmaceutical company was able to expand its use of email and web access to communicate with doctors in a timely, personalized manner via the video channel.